Weight Management

Addressing muscle loss associated with GLP-1 medication use

April 2, 2024 - Glucagon-like peptide-1 (GLP-1) receptor agonists — also known as GLP-1 drugs — have gained a significant amount of attention in recent years because of their utility in managing type 2 diabetes (T2D) and, even more so, in weight management for overweight or obese adults. Despite the scientifically proven benefits of these drugs, there are many challenges posed by their...

Read More


More Articles

FDA expands Wegovy indications, adding cardiovascular disease

by Veronica Salib

On March 8, 2024, the United States FDA expanded approval of Wegovy (semaglutide), making it the first weight loss drug that is FDA-approved for obese and overweight patients at high risk for heart...

GLP-1 Medication Use Is Linked with Lower Anxiety, Depression Rates

by Veronica Salib

On Tuesday, February 6, 2024, Epic Research published the results of a dual-team Cosmos study, highlighting that taking certain glucagon-like peptide-1 (GLP-1) receptor agonists may reduce the chances...

Patients Maintain Weight Loss One Year After Discontinuing GLP-1 Drugs

by Veronica Salib

Earlier this week, Epic Research published a dual-team Cosmos study assessing how stopping glucagon-like peptide-1 (GLP-1) receptor agonists, sometimes called GLP-1 drugs, can impact long-term weight...

Exploring and Managing GLP-1 Receptor Agonists in Weight Loss

by Veronica Salib

Over the past few years, weight loss drugs like Ozempic and Wegovy have received extensive attention in mainstream media for their weight loss effects. Beyond attention from the general public, this class of medications, the glucagon-like...

Mayo Clinic Launches Weight Loss Prescription Program

by Veronica Salib

On January 16, 2024, the Mayo Clinic Diet, a weight loss program developed and approved by the Mayo Clinic, announced the beta launch of the Mayo Clinic Diet Medical Weight Loss Rx Program. The growing...

FDA Investigates the Safety of GLP-1 Weight Loss Drugs

by Veronica Salib

Yesterday, on January 11, 2024, the United States FDA issued a drug safety communication updating the public on an ongoing investigation of glucagon-like peptide-1 receptor agonists. The administration...

Roche Expands Obesity Portfolio Through $2.7 Billion Carmot Acquisition

by Veronica Salib

On December 4, 2023, Roche revealed that it entered into definitive merger agreements with Carmot Therapeutics. According to the company’s press release, it will acquire Carmot and its gamut of...

FDA Approves New Weight Loss Drug: Zepbound

by Veronica Salib

On November 8, 2023, the United States Food and Drug Administration (FDA) approved Eli Lilly’s newest weight loss drug, Zepbound. The newly approved drug uses the same active ingredient as...

Are Therapeutic Advancements Impacting the Demand for Surgery?

by Veronica Salib

According to the 2023 Trilliant Health report on trends shaping the health economy, the overall demand for surgical procedures has declined from 2017 to 2021. Despite declining rates of surgical interventions, the national disease burden...

Psychiatrists Prescribe or Recommend Ozempic, Other Weight Loss Drugs

by Veronica Salib

On November 3, 2023, the New York Times broke a story analyzing the role of Ozempic and other weight loss drugs in mental health or psychiatric care. Upon reaching out to 13 psychiatric departments at...

Online Vendors Sell Unapproved GLP-1 Drugs, FDA Issues Warnings

by Veronica Salib

Last week, the United States Food and Drug Administration (FDA) issued two warning letters to online vendors selling unauthorized versions of semaglutide and tirzepatide, active ingredients in...

Semaglutide Treatment Reduces Heart Failure Symptoms in Obese Patients

by Veronica Salib

Yesterday, the New England Journal of Medicine published the results of a randomized study, which revealed that semaglutide can help manage heart failure symptoms in obese patients with preserved...

Guiding Obesity Management by Understanding Weight Loss Drugs

by Veronica Salib

As the popularity of weight management drugs, including Ozempic, continues to rise, clinicians and healthcare professionals need a guide to the obesity drug landscape. The nuanced field of weight management continues to become more and...

Retatrutide Helps Patients Achieve 17.5% Weight Reduction at 24 Weeks

by Veronica Salib

A phase 2 clinical trial published in the New England Journal of Medicine revealed that retatrutide, Eli Lilly’s newest weight loss drug, helped patients achieve a 17.5% weight reduction in 24...

Recent Articles